NCT03562832
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with unstable intracranial disease that requires treatment or CNS disease that includes symptomatic epilepsy- see trial for details
https://ClinicalTrials.gov/show/NCT03562832